disulfiram has been researched along with 2019 Novel Coronavirus Disease in 10 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Severe acute lung injury has few treatment options and a high mortality rate." | 6.82 | Disulfiram inhibits neutrophil extracellular trap formation and protects rodents from acute lung injury and SARS-CoV-2 infection. ( Adrover, JM; Bram, Y; Carrau, L; Chandar, V; Daßler-Plenker, J; Egeblad, M; Houghton, S; Lyons, SK; Merrill, JR; Redmond, D; Schwartz, RE; Shevik, M; tenOever, BR, 2022) |
| "Severe acute lung injury has few treatment options and a high mortality rate." | 2.82 | Disulfiram inhibits neutrophil extracellular trap formation and protects rodents from acute lung injury and SARS-CoV-2 infection. ( Adrover, JM; Bram, Y; Carrau, L; Chandar, V; Daßler-Plenker, J; Egeblad, M; Houghton, S; Lyons, SK; Merrill, JR; Redmond, D; Schwartz, RE; Shevik, M; tenOever, BR, 2022) |
| "Lactoferrin (LF) is a multifunctional glycoprotein with potent antibacterial and anti-inflammatory activities that acts by neutralizing circulating endotoxins and activating cellular responses." | 1.62 | Disulfiram-loaded lactoferrin nanoparticles for treating inflammatory diseases. ( Fang, YF; Huang, YZ; Ou, AT; Tang, XP; Wang, R; Zhang, JX; Zhang, M; Zhao, PF; Zhao, YG, 2021) |
| "Disulfiram is an approved oral drug used to treat alcohol use disorder that is a potent anti-inflammatory agent and an inhibitor of the viral proteases." | 1.62 | Disulfiram use is associated with lower risk of COVID-19: A retrospective cohort study. ( Bell, S; Brophy, M; Do, N; Dubreuil, M; Fillmore, N; La, J; Lieberman, J; Mehta, G; Nguyen, V; Sander, C; Shen, C; Strymish, J; Wu, H, 2021) |
| "Patients with alcohol use disorders, on disulfiram, might experience disulfiram ethanol like reactions with alcohol-based sanitizers." | 1.62 | Disulfiram Ethanol Reaction with Alcohol-Based Hand Sanitizer: An Exploratory Study. ( Balhara, YPS; Basu, D; Bn, S; Ghosh, A; Mahintamani, T; Mattoo, SK; Mishra, E; Roub, FE; Sharma, B, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 10 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jin, Z | 1 |
| Du, X | 1 |
| Xu, Y | 1 |
| Deng, Y | 1 |
| Liu, M | 1 |
| Zhao, Y | 1 |
| Zhang, B | 1 |
| Li, X | 1 |
| Zhang, L | 1 |
| Peng, C | 1 |
| Duan, Y | 1 |
| Yu, J | 1 |
| Wang, L | 1 |
| Yang, K | 1 |
| Liu, F | 1 |
| Jiang, R | 1 |
| Yang, X | 2 |
| You, T | 1 |
| Liu, X | 2 |
| Bai, F | 1 |
| Liu, H | 1 |
| Guddat, LW | 1 |
| Xu, W | 1 |
| Xiao, G | 1 |
| Qin, C | 1 |
| Shi, Z | 1 |
| Jiang, H | 1 |
| Rao, Z | 1 |
| Yang, H | 1 |
| Pillaiyar, T | 1 |
| Wendt, LL | 1 |
| Manickam, M | 1 |
| Easwaran, M | 1 |
| Ou, AT | 1 |
| Zhang, JX | 1 |
| Fang, YF | 1 |
| Wang, R | 1 |
| Tang, XP | 1 |
| Zhao, PF | 1 |
| Zhao, YG | 1 |
| Zhang, M | 1 |
| Huang, YZ | 1 |
| Fillmore, N | 1 |
| Bell, S | 1 |
| Shen, C | 1 |
| Nguyen, V | 1 |
| La, J | 1 |
| Dubreuil, M | 1 |
| Strymish, J | 1 |
| Brophy, M | 1 |
| Mehta, G | 1 |
| Wu, H | 1 |
| Lieberman, J | 1 |
| Do, N | 1 |
| Sander, C | 1 |
| Adrover, JM | 1 |
| Carrau, L | 1 |
| Daßler-Plenker, J | 1 |
| Bram, Y | 1 |
| Chandar, V | 1 |
| Houghton, S | 1 |
| Redmond, D | 1 |
| Merrill, JR | 1 |
| Shevik, M | 1 |
| tenOever, BR | 1 |
| Lyons, SK | 1 |
| Schwartz, RE | 1 |
| Egeblad, M | 1 |
| Cvek, B | 1 |
| Brewer, C | 1 |
| Streel, E | 1 |
| Balhara, YPS | 2 |
| Singh, S | 1 |
| Narang, P | 1 |
| Ghosh, A | 1 |
| Mahintamani, T | 1 |
| Roub, FE | 1 |
| Basu, D | 1 |
| Bn, S | 1 |
| Mattoo, SK | 1 |
| Mishra, E | 1 |
| Sharma, B | 1 |
| Tamburin, S | 1 |
| Mantovani, E | 1 |
| De Bernardis, E | 1 |
| Zipeto, D | 1 |
| Lugoboni, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of SPI-1005 in Moderate COVID-19 Patients[NCT04484025] | Phase 2 | 60 participants (Anticipated) | Interventional | 2021-10-12 | Enrolling by invitation | ||
| A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of SPI-1005 in Severe COVID-19 Patients[NCT04483973] | Phase 2 | 60 participants (Anticipated) | Interventional | 2021-08-27 | Enrolling by invitation | ||
| DISulfiram for COvid-19 (DISCO) Trial: A Phase 2 Double-Blind, Randomized Placebo-Controlled Trial of Disulfiram Compared to Standard Care in Patients With Symptomatic COVID-19[NCT04485130] | Phase 2 | 11 participants (Actual) | Interventional | 2021-08-18 | Terminated (stopped due to Low COVID case numbers, competing COVID treatments available) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The severity of COVID-19 symptoms will be recorded on a 5-point symptom severity scale at each visit for each participant. A question about how much the symptoms bother the participants will be asked. The participant will rank 1 as not at all, 2 as a little bit, 3 as somewhat, 4 as quite a bit and 5 as very much. Higher values represent worse outcomes. Scales are combined to compute a total score at Day 0 and Day 31. A change of the median is reported." (NCT04485130)
Timeframe: Day 0 and Day 31
| Intervention | units on a scale (Median) |
|---|---|
| Cohort 1: Disulfiram | -2.60 |
| Cohort 1: Placebo | -2.14 |
Change in copies of SARS-CoV-2 PCR virus per mL between Baseline and Day 31. (NCT04485130)
Timeframe: Day 0 and Day 31
| Intervention | copies/mL (Mean) |
|---|---|
| Cohort 1: Disulfiram 1000 mg | -20.89 |
| Cohort 1: Placebo | -20 |
Change in plasma inflammatory biomarker levels (e.g., IL-6, IL-1b) at days 5, 15, and 31. (NCT04485130)
Timeframe: Day 0 and Day 31
| Intervention | fold change (Median) | |
|---|---|---|
| Change in IL-6 (pg/mL) Day 0 to 31 | Change in IL-1B (pg/mL) Day 0 to 31 | |
| Cohort 1: Disulfiram 100 mg | -0.1186 | -0.1402 |
| Cohort 1: Placebo | -0.0215 | 0.0268 |
The safety and tolerability of a 5 day course of disulfiram. The number of adverse events and their grade will be determined for each participant. (NCT04485130)
Timeframe: Day 0 and Day 31
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| AE Grade 3 or Higher | AE Grade 1 or 2 | |
| Cohort 1: Disulfiram 1000 mg | 0 | 4 |
| Cohort 1: Placebo | 1 | 1 |
2 reviews available for disulfiram and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.
Topics: Antiviral Agents; Chemistry, Pharmaceutical; COVID-19; Disease Outbreaks; Drug Repositioning; Humans | 2021 |
Disulfiram inhibits neutrophil extracellular trap formation and protects rodents from acute lung injury and SARS-CoV-2 infection.
Topics: Acetaldehyde Dehydrogenase Inhibitors; Acute Lung Injury; Animals; COVID-19; Disease Models, Animal; | 2022 |
8 other studies available for disulfiram and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Structure of M
Topics: Antiviral Agents; Betacoronavirus; Cells, Cultured; Coronavirus 3C Proteases; Coronavirus Infections | 2020 |
Structure of M
Topics: Antiviral Agents; Betacoronavirus; Cells, Cultured; Coronavirus 3C Proteases; Coronavirus Infections | 2020 |
Structure of M
Topics: Antiviral Agents; Betacoronavirus; Cells, Cultured; Coronavirus 3C Proteases; Coronavirus Infections | 2020 |
Structure of M
Topics: Antiviral Agents; Betacoronavirus; Cells, Cultured; Coronavirus 3C Proteases; Coronavirus Infections | 2020 |
Structure of M
Topics: Antiviral Agents; Betacoronavirus; Cells, Cultured; Coronavirus 3C Proteases; Coronavirus Infections | 2020 |
Structure of M
Topics: Antiviral Agents; Betacoronavirus; Cells, Cultured; Coronavirus 3C Proteases; Coronavirus Infections | 2020 |
Structure of M
Topics: Antiviral Agents; Betacoronavirus; Cells, Cultured; Coronavirus 3C Proteases; Coronavirus Infections | 2020 |
Structure of M
Topics: Antiviral Agents; Betacoronavirus; Cells, Cultured; Coronavirus 3C Proteases; Coronavirus Infections | 2020 |
Structure of M
Topics: Antiviral Agents; Betacoronavirus; Cells, Cultured; Coronavirus 3C Proteases; Coronavirus Infections | 2020 |
Disulfiram-loaded lactoferrin nanoparticles for treating inflammatory diseases.
Topics: Acetaldehyde Dehydrogenase Inhibitors; Animals; Anti-Inflammatory Agents; Biomimetic Materials; Coli | 2021 |
Disulfiram use is associated with lower risk of COVID-19: A retrospective cohort study.
Topics: Adult; Alcoholism; Cohort Studies; COVID-19; COVID-19 Drug Treatment; Disulfiram; Female; Humans; Ma | 2021 |
Multiple deadlocks in the development of nonprofit drugs.
Topics: COVID-19; Delivery of Health Care; Disulfiram; Humans; Organizations, Nonprofit; Pandemics | 2022 |
Is Alcohol in Hand Sanitizers Absorbed Through the Skin or Lungs? Implications for Disulfiram Treatment.
Topics: Administration, Inhalation; Betacoronavirus; Breath Tests; Coronavirus Infections; COVID-19; Disulfi | 2020 |
Effect of lockdown following COVID-19 pandemic on alcohol use and help-seeking behavior: Observations and insights from a sample of alcohol use disorder patients under treatment from a tertiary care center.
Topics: Adult; Alcohol Deterrents; Alcoholic Beverages; Alcoholism; Coronavirus Infections; COVID-19; Disulf | 2020 |
Disulfiram Ethanol Reaction with Alcohol-Based Hand Sanitizer: An Exploratory Study.
Topics: 2-Propanol; Adult; Alcohol Deterrents; Alcoholism; COVID-19; Cross-Sectional Studies; Disulfiram; Dr | 2021 |
COVID-19 and related symptoms in patients under disulfiram for alcohol use disorder.
Topics: Alcoholism; COVID-19; Disulfiram; Humans; SARS-CoV-2 | 2021 |